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Aim: The aims of this study were to assess the impact of two follow-up infant formulas based on cow milk fat,
vegetable oils and different docosahexaenoic (DHA) and arachidonic (ARA) acid content on red blood cell
membrane fatty acid composition, and determine the percent saturated fatty acid (SFA) incorporation into the
membrane.
Study design: Thiswas a double-blind, randomized, controlled, parallel-group clinical trial. Infants received treat-
ment or control product for at least four months before the age of six months. The control group (n = 25) re-
ceived standard infant formula (FA) and the treatment group (n = 24) received the same formula
supplementedwith higherDHA andARA content (FB). The reference group (n=47) consisted of normal healthy
exclusively breastfed infants.
Outcome measure: Red blood cell membrane fatty acid composition was determined by capillary gas
chromatography.
Results:Ninety-six infants completed the study (FA, 25; FB, 24; reference, 47). Higher DHA content reﬂected
higher DHA percentage in the red blood cell membrane. Breast milk and FB did not show any signiﬁcant dif-
ferences in DHA content. ARA percentage was higher in breastfed infants and palmitic acid percentage was
higher in FB- compared with FA-fed infants.
Conclusion: DHA and palmitic acid percent distributions were higher in the red blood cell membrane of in-
fants receiving FB. DHA percent distribution was not signiﬁcantly different in FB-fed and breastfed infants.
SFA percent distribution was not signiﬁcantly different when comparing both formulas with breast milk.
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Fatty acids1. Introduction
In the last decades, there has been growing concern about the fatty
acid composition of infant formulas, which are normally used when
breastfeeding must be either replaced or complemented following
medical advice. Breast milk is the main reference for infant feeding,
since it has the best concentration of nutrients and bioactive factors [1].
The fetus, thenewborn andbreast-fed infantsmust receive sufﬁcient
amounts of long-chain polyunsaturated fatty acids (LCPUFA) to sustain
optimal visual and cognitive development. In this sense, breast milk is
highly recommended as a source of LCPUFA. When breastfeeding is
not possible, the current recommendation is the provision of formulasnzález).
.with adequate docosahexaenoic acid (DHA) and arachidonic acid
(ARA) levels [2].
Studies supporting the advantages of breastfeeding have focused on
the concentration of LCPUFA in human breast milk, particularly DHA
and ARA [3]. These two account for 20% of the brain fatty acid content
and are involved in neurodevelopment, promoting healthy neuronal
growth, repair and myelination [4]. At the end of pregnancy, ARA is
the predominant PUFA in the brain, but DHA accretion after birth
makes it the main PUFA in the adult brain, representing approximately
50–60% of the brain's dry weight [5].
Breast milk fat is better absorbed than infant formula fat. Despite
similarities in their fatty acid composition, the structure of human
milk triacylgycerols is different. Palmitic acid (hexadecanoic acid) is
one of the main components of maternal milk, representing around
25% of the lipid proﬁle, fromwhich 60–85% is in sn-2 position of triacyl-
glycerols [6,7]. Addition of palm oil (high palmitic acid content) to
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milk. However, a critical aspect of infant formulas to mimic humanmilk
composition is the bioavailability of nutrients, in this case, fatty acids
[8–10].
Triacylglycerols (palmitic acid in sn-2 position) in human milk are
digested by pancreatic lipase, which hydrolyzes them on the 1 and 3
carbons and releases saturated fatty acids (SFA), both palmitic and
stearic acid, as sn-2-monoacylglycerols. These will later formmixedmi-
celles with bile salts to be absorbed [8]. On the other hand, the greatest
part of palmitic acid from palm oil used in infant formulas is present in
sn-1 and sn-3 positions of triacylglycerol [11,12], becoming free fatty
acid after hydrolysis. Free fatty acids bind to calcium in a process of sa-
poniﬁcation to form a non-absorbable complex that contributes to the
low absorption of fat and calcium, lower weight gain and hardening of
stools. The effect of palm oil has been shown in term and pre-term
babies and experimental animals [12–14]. In cow milk, the concentra-
tion of palmitic acid in sn-2 position is above 45% fat [15].
The role of SFA in milk and breast fat has been recently reviewed,
with an emphasis on their relevance and beneﬁts [16]. More recently,
focusing in palmitic acid, SFA have been reported as an essential compo-
nent of membrane, secretory and transport lipids, with crucial roles in
protein palmitoylation and signal molecules [17]. Further, the author
raises some questions, namely, why the human fetus synthesizes and
accumulates 16:0, and the human mammary gland invests in speciﬁc
pathways to provide the infant with 16:0, proposing that those ques-
tions are important for developmental biology, with broad implications
for the nutritional care of infants that involve fatty acids that alter
sources of metabolic energy, and the growing tissue and plasma lipids
[17].
We analyzed the percentage of palmitic acid at sn-2 position of triac-
ylglycerols in infant formulas from the Argentinean market that are
used as breast-milk substitutes during the ﬁrst six months after deliv-
ery. We found that formulas with vegetable oils as basic source of lipids
had b15% of palmitic acid at sn-2 position,whereas formulas containing
a blend with milk fat had 48% of palmitic acid at sn-2 position [18].
The best approach to study fatty acid incorporation into the tissues,
particularly the central nervous system, is through the study of red
blood cell membrane fatty acids, which are considered representative
of the composition of brain cell membranes [19]. Therefore, it would
be important to know whether higher DHA and ARA content in infant
formulas results in higher red blood cell membrane fatty acid percent-
age as well as to determine the percent SFA incorporation into the
membrane.
The aim of the present study was to assess the impact of two follow-
up infant formulas based on cow milk fat, vegetable oils and different
DHA and ARA content on red blood cell membrane fatty acid composi-
tion, and to determine the percent incorporation of SFA into the
membrane.
2. Patients and methods
2.1. Study design and protocol
Healthy term infants being seen for routine follow-up appointments
since the ﬁrst month of life at the Health Observatory of IDIP (Instituto
de Desarrollo e Investigaciones Pediátricas, La Plata's Children Hospital,
Buenos Aires, Argentina) were recruited for a double-blind, random-
ized, controlled, parallel-group clinical trial during December 2012–No-
vember 2014.
Both gestational age and birth weight of infants were normal
(N37–b42 weeks and ≥2500–b4000 g, respectively). Mothers
were also healthy and N18 years of age. Written informed parental
consent was obtained for each infant before inclusion.
Exclusion criteria included inadequate height-for-age and weight-
for-age indices according to the World Health Organization (WHO)
charts; infants with acute infections within 15 days before recruitment;chronic diseases; antibiotic or vitamin treatment; a birth weight
b2500 g; pathological fetal and neonatal history; anemia not related
with nutrition; diagnosis or ongoing studies of genetic alterations;
lack of written informed parental consent and mothers with chronic
diseases.
The study protocol was approved by IDIP's Institutional Research
Review Board and registered in the Ministry of Health of the prov-
ince of Buenos Aires. It was performed in accordance with the ethical
standards laid down in the 1948 Universal Declaration of Human
Rights, the Nüremberg Code and the 1964 Declaration of Helsinski
and successive revisions and amendments.
Participantswere controlled and enrolled since theﬁrstmonth of life
at IDIP's Health Observatory. Breastfed infants were followed-up with-
out any intervention. At the timewhenmothers independently decided
to cease breastfeeding and introduce infant formula, infants were ran-
domly assigned to receive either a standard infant formula (control
group, FA) or an infant formula supplemented with DHA and ARA
(treatment group, FB) to enhance the levels of both fatty acids. A refer-
ence group was formed of infants who continued to be exclusively
breastfed up to six months (non-randomized). Random allocation of
study participants to the intervention was performed with EPIDAT 3.1
(1:1 allocation ratio). None of the two groups received complementary
foods other than formula.
Physical examination included infant weight, length and head cir-
cumference measurement at baseline (age 2–4 weeks) and at monthly
intervals throughout the intervention until the age of 6 months. These
measurements were used to calculate height-for-age, weight-for-age
andweight-for-height indices, and plotted into reference Z-score tables
based on the WHO Child Growth Standard, using WHO Anthro 2007
Version.
Nutritional status was assessed using anthropometric indices of
height-for-age, weight-for-age andweight-for-height; Z-scoreswere cal-
culatedwith the EPINUT program in Epi Info (version 3.3, 2004). Stunting
was deﬁned as a height-for-age (Z-score), underweight as a weight-for-
age (Z-score), and wasting as a weight-for-height (Z-score), on the
basis of the WHO Child Growth Standard 2007 Version.
Infants were dropped out of the trial if they were subsequently
found to have received non-compliant feeding during the intervention,
or to have moved to an unidentiﬁed address. Infants on any of the two
formulas had to fulﬁll supplementation for a minimum of 4 months be-
fore the age of 6months and breastfeed nomore than once a day. Exclu-
sive breastfeeding had to be sustained until the age of 6 months.
Infant formulas were developed and produced by Sancor CUL and
had the following composition: Formula A contained (w/w) 66.81%
milk fat, 33.19%vegetable oil (32.44% canola and sunﬂower 50/50%mix-
ture), and 0.75% oil as source of ARA and DHA, obtained from fungi and
microalgae. Formula B contained (w/w) 65.41%milk fat, 34.59% vegeta-
ble oil (33.05% canola and sunﬂower 50/50% mixture), 1.24% oil as
source of ARA and DHA obtained from fungi and microalgae, and
0.30% oil with high DHA content from microalgae (which contains
palmitic acid).
Data for maternal milk composition were taken from 32 mothers of
exclusively breastfed infants. In all cases, samples were taken 3 months
after delivery. Breast milk samples taken more than a week before or
after the third monthwere discarded. Table 1 shows the fatty acid com-
position of supplemented formulas and the breast milk composition of
32 exclusively breastfed infants.
2.2. Breast milk sample collection
Before sample collection, mothers washed their hands and breasts
with soap. Milk collection was carried out with a sterile automatic
breast milk pumper with a vacuum regulator (mini electric breast
pump, MEDELA Inc. USA), polystyrene suction funnels and screw-top
bottles adapted to suction funnels for direct collection of milk. The bot-
tles and the suction funnels were autoclaved before use. The milk
Table 1
Composition of supplemented formulas (SanCor CUL) and breast milk. Data are expressed
in g/100 ml (*) and percent of total fatty acids (**).
Fatty acids Formula A
Control group
Formula B
Treatment group
Breast milk
Reference group
Total fat * 3.78 3.70 3.57
SFA* (**) 1.62 (42.86) 1.62 (43.78) 1.52 (42.64)
MUFA* (**) 1.41 (37.30) 1.37 (37.00) 1.27 (35.6)
PUFA* (**) 0.66 (17.46) 0.64 (17.30) 0.78 (22.1)
Trans* (**) 0.09 (2.38) 0.08 (2.16) 0.02 (0.72)
C10:0* (**) 0.07 (1.85) 0.05 (1.35) 0.02 (0.69)
C12:0* (**) 0.08 (2.12) 0.06 (1.62) 0.17 (4.66)
C14:0* (**) 0.27 (7.14) 0.22 (5.95) 0.21 (5.86)
C16:0* (**) 0.74 (19.58) 0.69 (18.65) 0.76 (21.42)
C18:2n6 LA* (**) 0.57 (15.32) 0.51 (13.81) 0.70 (19.64)
C18:3n3 ALA*(**) 0.095 (2.51) 0.066 (1.78) 0.02 (0.66)
C20:4n6ARA*(**) 0.0086 (0.23) 0.014 (0.38) 0.016 (0.46)
C22:6n3DHA*(**) 0.0036 (0.09) 0.010 (0.27) 0.006 (0.17)
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approximately) and immediately aliquoted in 10 mL tubes using sterile
material, frozen and stored at−80 °C for later analysis [20,21].
2.3. Blood samples
Venous blood samples (1 mL) were taken at 6 months of age during
the control visits at the Health Observatory and collected in tubes con-
taining 5% EDTA, pH 7. Blood was centrifuged within 30 min of extrac-
tion to separate plasma from red blood cells. The pellet was washed
with sodium chloride 0.9%, centrifuged three times and kept at
−70 °C until processing.
2.4. Red blood cell membrane fatty acid analysis
Redblood cellmembrane fatty acid compositionwasdeterminedby ex-
tractionofmembrane lipidswith amixtureof chloroform/methanol (2/1, v/
v) [22]. Partition was performed with 20% v/v distilled water. The upper
methanolic phase was discarded. The remaining chloroformic phase was
evaporated to dryness under a nitrogen stream. Fatty acid methyl esters
(FAME) were obtained after trans-methylation by using boron triﬂuoride
10% methanol [23]. FAME were analyzed with gas chromatography (GC
System, 7890A Series, Agilent Technologies, Wilmington, Delaware, USA);
ﬂame ionization detection (FID) was applied. A 60-m capillary column
was used (DB-23; Agilent Technologies), calibrated against a standard con-
taining 37 FAME, ranging in chain length from 4 to 24 carbon atoms
(Supelco 37 Component Fame Mix; Supelco, Bellefonte—Pennsylvania,
USA). Quantiﬁcationwas performed using the peak areas automatically re-
trieved from an integrator coupled to the chromatograph. The fatty acid re-
sults were expressed as percentages of total fatty acids detected.
2.5. Milk fatty acid analysis
Fatty acidswere extracted from 500 μL ofmilkwith amixture of chlo-
roform/methanol (v/v, 2:1) [22]. After lipid extraction, the chloroform
phase was evaporated under nitrogen current; fatty acids were saponi-
ﬁedwithpotassiumhydroxide in 10%methanol andacidiﬁedwithhydro-
chloric acid to neutralize. FAMEwere extracted twice with n-hexane and
obtained after trans-methylation of total lipids by using boron triﬂuoride
10%methanol [23] for 1 h at 80 °C. Theywere separated and quantiﬁed as
previously described for the red blood cell membrane.
2.6. Sample size
Sample size was estimated to obtain a 90% power and a 95% conﬁ-
dence interval and to detect differences of 0.9 in DHA values between
the control and the treatment formulas, assuming a standard deviation0.94 for DHA [24]. Thus, the required sample size was 25 infants per
group, totalling 75 infants.
2.7. Statistical analyses
Data were processedwith SPSS, version 18.0 forWindow. Red blood
cell membrane fatty acids were grouped as follows: SFA, C14:0, C15:0,
C16:0, C17:0, C18:0, C20:0, C22:0, C24:0; monounsaturated (MUFA),
C16:1n7, C18:1n9 cis and trans, C20:1n9, C22:1n9, C24:1n9; PUFA
were divided into Omega 6 (C18:2n6 cis and trans, C18:3n6, C20:2n6,
C20:3n6, C20:4n6, C22:2n6) and Omega 3 (C18:3n3, C:20:3n3;
C20:5n3, C22:6n3).
The normality of each variable was evaluatedwith the Shapiro–Wilk
test. Means and standard deviations were used for comparisons be-
tween groups. ANOVA was used to assess the effects of the dietary
groups. Between-pair comparisons were performed with corrected p-
value by Scheffé method.
In all cases, results with a signiﬁcance level of p b 0.05 were consid-
ered statistically signiﬁcant. Fatty acid levels were reported as percent-
age of total fatty acids analyzed.
3. Results
Of the 109 infants enrolled, 96 completed the study. Infants whose
mothers chose not to provide breastmilkwere randomly assigned to re-
ceive a standard formula (control group [FA]; n = 29) or formula with
higher DHA and ARA content (treatment group [FB]; n = 28), while in-
fants who continued to be exclusively breastfed constituted the refer-
ence group (n = 47). During the trial, 13 infants were dropped out
(Fig. 1). Sample characteristics and nutritional condition after the inter-
vention are described in Table 2. We did not observe statistically signif-
icant differences among groups.
Table 3 shows the percentage of red blood cell membrane fatty acids
according to diet.
The percentage of palmitic acid was higher in FB-fed infants com-
pared with FA-fed ones. Conversely, the percentage of stearic acid was
higher in FA-fed infants. Total SFA were similar in both groups. No sig-
niﬁcant differences were found when comparing both formulas with
breast milk.
The percentage of MUFA was signiﬁcantly higher in FA-fed com-
pared with FB-fed and breastfed infants. Differences between FB and
breast milk were not signiﬁcant.
The percentage ofω3 PUFA andDHAwasmarkedly higher in infants
fed FB compared with FA (control). We could not detect differences be-
tween FB and breastfed infants (reference).
Finally, the percentage of ω6 PUFA was similar in FA-, FB- and
breastfed infants. However, ARA percentagewas lower in FB-fed infants
as compared with the control and the reference groups.
4. Discussion
In this study, we evaluated the impact of two infant formulas based
on cowmilk fat, vegetable oil and different DHA and ARA content on red
blood cell membrane fatty acid composition, and determined the per-
cent SFA incorporation into the membrane. As a reference, we included
a group of exclusively breastfeeding infants and also assessed maternal
milk composition. To our knowledge, there are no previous studies in
our region reporting the impact of type of feeding on red blood cell
membrane fatty acid composition in healthy, well-nourished infants.
Our results show that the percentage ofω3 PUFA and DHA in the red
blood cell membrane was markedly higher in infants fed FB compared
with FA (control). We could not detect differences between FB and
breastfed infants (the reference). Our results also agree with those of
other authors [25] in the sense that higher DHA content reﬂects higher
DHA percentage in the red blood cell membrane. Comparison of FB-
Fig. 1. Flow chart of participant registration, randomization and follow-up.
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in the red blood cell membrane. However, ARA percentage was lower.
The same results were reported by Miller et al. [26] when comparing
formulas supplemented or not with DHA and ARA, probably due to their
competitive nature because, when both are available, the membrane will
preferably incorporateDHA [26]. However, DHA andARApercentagewas
higher in the red blood cell membrane of exclusively breastfed infants as
compared with infants fed with either formula. The weakness in Miller's
study is concerned with the lack of measurement of fatty acid levels in
breast milk. Therefore, diets with a high omega-3/omega-6 ratio result
in increased omega-3 and DHA contents in red blood cells [27,28].
Regarding palmitic acid, its percentage in the red blood cellmembrane
was higher in FB- compared with FA-fed infants, and its content was
higher in FB, probably because the source of DHA contains palmitic acid,
which might ﬁnally increase the total percentage of this fatty acid. How-
ever, stearic acid was higher in FA-fed infants and consequently, totalTable 2
Characteristics and nutritional condition of infants enrolled in the study 4 months after receivi
Formula A Control group Formula B
Sex (male) 56% 54.2%
Age (months) 6.10 ± 1.18 6.32 ± 0.3
Weight (g) 7782.04 ± 1081.98 7937.71 ±
Z-score weight/height 0.74 ± 2.64 0.48 ± 0.8
Z-score height/age −0.27 ± 3.14 −0.21 ± 1
Z-score weight/age 0.09 ± 1.38 0.16 ± 0.8SFA were similar in both groups. No signiﬁcant differences were found
in SFA percentage when comparing both formulas with breast milk.
A recent report determined the effect of an infant formula supple-
mented with a mixture of dairy lipids and plant oils on the erythrocyte
membrane omega-3 fatty acid proﬁle in full-term infants [25]. However,
the study does not include a reference group of exclusively breastfed in-
fants, which is one of the strengths of our research, together with the
fact that we also studied the lipid composition of maternal milk.
Hoffman et al. [24] studied the percent distribution of red blood cell
membrane fatty acids in infants fed two formulas with different PUFA
content. The same as in our study, they found a higher percentage of
DHA in infants fed the formula with greater PUFA content; the authors
also reported that the formula with lower DHA content had a greater
percentage of precursors (LA-ALA), not sufﬁcient to equal the amount
produced by the pre-formed DHA. These authors neither presented a
reference group nor compared their results with breast milk.ng FA, FB or breast milk.
Treatment group Breast milk Reference group P-value
40.4% 0.245
3 6.34 ± 0.59 0.326
814.50 7678.09 ± 970.59 0.838
7 0.37 ± 0.99 0.710
.09 −0.41 ± 1.02 0.811
9 −0.04 ± 0.9 0.977
Table 3
Red blood cell membrane fatty acid composition in the study groups.
Fatty acid Mean ± SD ANOVA P-value
Breast milk Reference group d/tn Formula A Control group d/tn Formula B Treatment group d/tn
C16:0 Palmitic 22.05 ± 3.00b 47/47 20.71 ± 2.11c 25/25 24.64 ± 3.59b,c 24/24 b0.0001
C18:0 Estearic 19.94 ± 3.04a 47/47 20.90 ± 2.09b 25/25 17.83 ± 3.64a,b 24/24 0.002
C18:1n9 cis 13.6 ± 2.70a1,a2 47/47 15.52 ± 2.51a1 25/25 15.53 ± 2.79a2 24/24 0.003
C20:4n6 ARA 20.55 ± 2.25c 47/47 19.87 ± 2.11b 25/25 17.42 ± 3.79b,c 24/24 b0.0001
C22:6n3 DHA 4.97 ± 1.14c 47/47 3.36 ± 1.29b,c 25/25 4.55 ± 1.60b 24/24 b0.0001
SFA 42.86 ± 4.14 47/47 42.82 ± 3.90 25/25 43.40 ± 6.70 24/24 ns
MUFA 16.83 ± 3.12c 47/47 19.86 ± 3.16a,c 25/25 17.75 ± 2.55a 24/24 b0.0001
ω3 PUFA 4.98 ± 1.14c 47/47 3.52 ± 1.29a,c 25/25 4.55 ± 1.60a 24/24 b0.0001
ω6 PUFA 35.24 ± 4.06 47/47 34.50 ± 2.37 25/25 34.34 ± 5.09 24/24 ns
Total PUFA 40.22 ± 4.07 47/47 38.01 ± 2.99 25/25 38.89 ± 5.42 24/24 ns
a , a1, a2 p ≤ 0.05, b p b 0.01, c p ≤ 0.0001 between-pair comparison with corrected p-value by Scheffé method.
d = detected, tn = total n, ns = not signiﬁcant.
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ARA were similar to those reported in the study by Hoffman et al. [24].
However, the formula used in the Miller et al. study [26] had higher
PUFA content. The Codex recommendation for standard infant formulas
suggests DHA supplementation not N0.5% of total fat content, without
proposing a minimal percentage [29].
A limitation of our study was the lack of infants fed formulas con-
taining only vegetable oils, since they present a very low percentage
of palmitic acid at sn-2 position, which could impact on the percentage
incorporated by the red blood cell membrane.
5. Conclusions
Comparison of two infant formulas based on cowmilk fat, vegetable oil
and different DHA and ARA content and assessment of their impact on red
blood cell membrane fatty acid composition showed that percent distribu-
tions of DHA and palmitic acid were higher in the formula with greater sup-
plementation (FB). DHA percentage was not signiﬁcantly different in FB-fed
and breastfed infants, and SFA percentage in the red blood cell membrane
was not different when comparing both formulas with breast milk.
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